Noor Ul Ain Rehman
Mon, January 19, 2026 astatine 3:19 AM CST 2 min read
For fiscal Q4 2025, the institution announced that it expects nett merchandise gross for VYJUVEK to beryllium betwixt $106 cardinal and $107 million, based connected preliminary unaudited fiscal information. VYJUVEK’s nett gross for the afloat twelvemonth 2025 is anticipated to beryllium betwixt the scope of $388 cardinal and $389 million. Krystal Biotech, Inc. (NASDAQ:KRYS) further reported that cash, currency equivalents, and investments are astir $955 cardinal arsenic of December 31, 2025.
The institution clarified that the preliminary unaudited results are based connected the archetypal investigation of operations conducted by the absorption for the twelvemonth ended December 31, 2025, and are taxable to adjustment. Krystal Biotech, Inc. (NASDAQ:KRYS) is acceptable to study its afloat fiscal results for fiscal Q4 and afloat twelvemonth 2025 successful February 2026.
Krystal Biotech, Inc. (NASDAQ:KRYS) is simply a biotechnology institution that develops and commercializes pharmaceutical products and offers the merchandise VYJUVEK, which is simply a topical gel that treats wounds successful big and pediatric patients (from birth) with dystrophic epidermolysis bullosa (DEB).
While we admit the imaginable of KRYS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This nonfiction is primitively published at Insider Monkey.

2 hours ago
1



.png)

English (CA) ·
English (US) ·
Spanish (MX) ·